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ABSTRACT
Objective: To investigate the possible electrophysiological background of the greater excitability of concentric and eccentric left ventricular 
hypertrophy types in relation to the asymmetric type. 
Methods: 187 patients with essential hypertension, without ishaemic heart disease were divided into three groups with regard to left ventricule 
type: concentric (relative wall thickness >0.42, interventricular septum/left ventricular posterior wall ≤1.3), eccentric (left ventricular diameter 
in systoles >32, relative wall thickness <0.42), asymmetric left ventricular hypertrophy (interventricular septum/left ventricular posterior wall 
>1.3), and three subgroups: mild (interventricular septum or left ventricular posterior wall 11-12 mm), moderate (interventricular septum or left 
ventricular posterior wall 13-14 mm) and severe left ventricular hypertrophy (interventricular septum or left ventricular posterior wall ≥15 mm). 
In all patients QT intervals, QT dispersion, left ventricular mass index and ventricular arrhythmias were measured. An upper normal limit for QT 
corrected interval: 450/460 ms for men/women; for QT dispersion: 70 ms.
Results: The QT corrected interval and QT dispersion were increased in severe concentric and eccentric left ventricular hypertrophy (443 and 
480 ms for QT corrected; 53 and 45 ms for QT dispersion, respectively), not significantly. QT dispersion in men with severe left ventricular hyper-
trophy was significantly enlarged (67.5 vs. 30 ms, p=0.047). QT interval was significantly longer in patients with complex ventricular arrhythmias 
(p=0.037).
Conclusion: No significant association of QT intervals or QT dispersion with the degree/type of left ventricular hypertrophy was found. QT cor-
rected interval and QT dispersion tend to increase proportionally to the left ventricular mass only in the concentric and eccentric type. 
(Anatolian J Cardiol 2015; 15: 33-9)
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Influence of the left ventricular types on QT intervals in  
hypertensive patients
Introduction
Marked left ventricular hypertrophy (LVH) is associated with 
potentially arrhythmogenic ventricular repolarization abnormali-
ties and may generate conditions for QT interval (QTi) prolonga-
tion and increase QT dispersion (QTd) (1, 2). Prolongation of QT 
corrected (QTc) interval and QTd are risk markers for malignant 
ventricular arrhythmias and sudden cardiac death (3, 4). QT 
prolongation and dispersion are indicators for abnormalities in 
ventricular repolarization. This could suggest the presence of 
functional reentrant proarrhythmic circuits. Increased hyperpo-
larization-activated cyclic nucleotide-gated channel activity in 
hypertrophied myocytes prolongs the repolarization of the ven-
tricular action potential and thereby may increase the arrhyth-
mogenic potential (5). Defined as the difference between the 
longest and shortest QTi measured in any lead of the 12-lead 
electrocardiogram, QTd reflects the inhomogeneity in ventricu-
lar repolarization. Both parameters include also depolarisation. 
Increased QTd has been shown to correlate positively to com-
plex ventricular arrhythmias in many clinical conditions (3, 6). 
QTd and QTi correlate with the left ventricular mass index 
(LVMI) determined echocardiographically in a group of selected 
patients with essential hypertension (7, 8). Normal QTd values 
vary extensively from 10 to 71 ms. QTd is higher in cardiac 
patients in comparison to normal subjects. The probability is that 
only explicitly abnormal values (i.e., those >100 ms) outside error 
margins may potentially have a practical value, suggesting a 
markedly abnormal repolarization (9). Scarce data was pub-
lished regarding QTc interval prolongation/QTd and complex 
ventricular arrhythmias in hypertensive patients with LVH (10, 
11), but which type of LVH has the greatest influence has been 
understudied (especially for the asymmetric type). The aim of 
this study was to investigate which type of LVH, considering at 
the same time the degree of LVH, induces the greatest QTi pro-
longation and QTd with a consequent proarrhythmic effect.
Methods
We performed an observational retrospective study. In a 
period of 5.5 years at the outpatient cardiology department sus-
pected LVH on electrocardiography was observed in 1606 hyper-
tensive patients. 1414 were excluded from the study for not sat-
isfying the strict inclusion criteria (one of those under). Patients 
with congestive heart failure, atrial fibrillation, known coronary 
disease (history of angina pectoris at rest or at exercise testing, 
previous myocardial infarction according to documents or con-
firmed by echocardiograhy, and percutaneous coronary inter-
ventions), heart surgery, valvular diseases and other cardiac 
diseases (hypertrophic obstructive cardiomyopathy and previ-
ous myocarditis) were excluded. Patients with diabetes mellitus, 
alcoholics (exclusion was based on their medical history, clini-
cal status and laboratory findings), patients with mental disor-
ders, those overusing non-antihypertensive drugs, patients with 
malignant or accelerated hypertension and those that had suf-
fered a stroke in the previous six months were also excluded. 
Patients with cancer, abnormal electrolytes, anemia, cardiopul-
monary diseases (chronic lung diseases, sleep apnea), serum 
creatinine >140 μmol/L and abnormal thyroid function, those 
taking medication that can increase QTc (antiarrhythmics; anti-
biotics: macrolides, quinolones; some antipsychotics and anti-
depressants) were also ruled out (12). Echocardiography con-
firmed the diagnosis of LVH in the remaining 194 patients. After 
exclusion of 7 patients taking amiodarone, remaining 187 (82 
men and 105 women, aged from 43 to 72 years) were included in 
the study. LVH was defined as LVMI greater than 132 g/m2 for 
men and greater than 109 g/m2 for women (moderately and 
severely abnormal) (13). Included were only patients who had 
essential hypertension and LVH. Hypertensive patients were 
those with blood pressure ≥140/90 mm Hg, measured three or 
more times by mercury sphygmomanometer, according to the 
guidelines of the European Society of Hypertension (ESH) and 
the European Society of Cardiology (ESC) (14). Blood pressure 
and heart rate were measured in office, and the mean arterial 
and pulse pressure were calculated. Upon previous patient’s 
informed consent and the approval of the School of Medicine 
Ethical Committee, medication was discontinued in all subjects 
for 48 hours prior to ECG exercise testing and Holter monitoring. 
Alcohol intake was prohibited during the same period. Patients 
were advised to contact the principal investigator by phone or in 
person in the event any symptoms should appear. 
Patients were divided into three main groups with regard to 
LVH type: concentric [relative wall thickness (RWT) >0.42 and 
interventricular septum/left ventricular posterior wall IVS/
LVPW ≤1.3], eccentric (left ventricular diameter in systoles >32 
mm and RWT <0.42) and asymmetric (IVS/LVPW >1.3), similar 
as in an earlier study (15) (and modified for asymmetric type). 
RWT was measured at end-diastole as the ratio of twice the 
thickness of LVPW/LVIDd left ventricular internal diastolic 
diameter, (LVIDd) (16). Each group was divided into subgroups 
according to the degree of LVH: mild (IVS or LVPW 11-12 mm), 
moderate (IVS or LVPW 13-14 mm) and severe (IVS or LVPW 
≥15 mm).
Echocardiographic measurements (“M-mode”, two-dimen-
sional and Doppler echocardiography) were performed and 
interpreted by three cardiologists working independently, with 
no knowledge of the study aim, compliant with the recommen-
dations of the American Society of Echocardiography (17). LVMI 
was calculated with the Devereux and Reichek’s formulae (18). 
In all patients a standard 12-lead ECG was performed after 
washout period for QTi measurements. ECG criteria to deter-
mine LVH according to Sokolow-Lyon and LV strain criterion 
were applied (19). ECG interpretation was performed manually 
and by a one qualified operator (cardiologist) who measured QTi 
in all 12 leads (and in 3 QRS complexes) with an accuracy of 20 
ms (20), followed by the assessment of mean QTi values. The 
QRS complex onset point was defined as the beginning of the 
QTi, and the T-wave endpoint as the QTi end. In the presence of 
U waves, QTi was measured to the nadir of the curve between 
the T and U waves. The measurements of the T wave variants 
were also performed according previously described methods 
(9). QTi was adjusted for heart rate using the Bazett’s square 
root correction formula: QTc=QT/√RR. QTd was defined as the 
difference between the shortest and the longest QTi in different 
leads (9). Lengths of up to 450 ms for men and up to 460 ms for 
women were considered normal QTc values (21), and for QTd up 
to 70 ms. All ECGs were obtained and QT intervals were mea-
sured in the morning. 
Finally, the examined variables were left ventricular mass 
(LVM), left ventricular mass index, left ventricular geometry, LVH 
degree, ventricular arrhythmias (VA) prevalence (according to 
Lown’s score), QTi and QTd. The type and duration of antihyper-
tensive and anti-arrhythmic therapy received by the patients 
before entering the study were recorded for the analysis of pos-
sible effects on the outcome. The indications for anti-arrhythmic 
drugs were ventricular and supraventricular arrhythmias.
Statistical analysis
The collected data were statistically evaluated using data 
analysis software system STATISTICA, version 7.1. StatSoft, Inc. 
(2005), www.statsoft.com. The data were normally distributed 
(distribution checked for normality by Shapiro-Wilks test) and 
therefore presented by means and standard deviation or with 
95% confidence interval. Categorical data were described with 
frequencies. Comparisons of numerical data were made using 
parametric ANOVA tests (one-way ANOVA for between-group 
comparisons and factorial ANOVA for between-group and 
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between-categories factors analysis). Results of nonparametric 
correlation (numerical by ordinal categories) were presented by 
Spearman rank correlation coefficient. The frequencies were 
analyzed by Yates corrected Pearson’s chi-square test or Fisher 
exact test, where suitable. The level of statistical significance 
was set at 0.05 in all analyses.
Results
Clinical characteristics of the patients are shown in Table 1.
Prior to the study, all the patients were using two or more 
drugs (Table 2).
There was no difference in the treatment duration between 
the three groups (p=0.858), or in the type of applied medication 
(Table 2). Antihypertensives were evenly distributed within 
groups with particular types of LVH (Pearson χ2 test, p=0.287). 
There was no difference in the frequencies of applied anti-
arrhythmics between groups or subgroups (Fischer test, p=0.347 
for propafenone in 20 patients; p=0.615 for verapamil in 8 
patients; and p=0.469 for metil-digoxin in 12 patients. Only two 
patients were treated with mexiletin. There was no difference 
between type and degree of LVH in drug concentrations (doses) 
(analysis of variance, p=0.440 and 0.120 for propafenone; p=0.180 
and 0.244 for verapamil; all patients were treated with the same 
dose of metil-digoxin (0.1 mg once a day). Two patients were 
taking combination of propafenon and digoxin, one patient was 
taking combination of verapamil and digoxin. Results were simi-
lar for beta-blockers in the frequencies of applied beta-blockers 
(Fisher’s test for atenolol p=0.069, for carvedilol p=0.469 and for 
bisoprolol p=0.328), and in drug concentrations (analysis of vari-
ance according to the type of LVH for atenolol p=0.291, for 
carvedilol p=0.430 and for bisoprolol p=0.347; analysis of vari-
ance according to the degree of LVH for atenolol p=0.049, for 
carvedilol 0.055 and for bisoprolol p=0.280). Only one patient was 
treated with sotalol (half life 12 hours).
LVMI differed significantly with regard to the degree of left 
ventricular hypertrophy (it increased), presenting a statistically 
significant difference in all correlation comparisons. LVMI also 
differed significantly with regard to LVH type. Patients with 
eccentric LVH had a statistically significantly higher LVMI than 
those with concentric LVH, while patients with asymmetric LVH 
presented no significant difference in relation to the concentric 
and eccentric type (Table 3).
The average QT and QTc intervals for the entire group of 
patients had borderline values. The average QTd remained 
within normal values (Table 4). The analysis of variance demon-
strated that the length of QTi and QTc interval did not differ with 
respect to type and degree of LVH. However, the analysis by 
Number, total 187 M 82 (43.8%) 
 F 105 (56.2%)
Parameter Mean value±SD
Age / year  66±6
BMI / kgm2 27.3±3.3
Elevated cholesterol (>5 mmol/L) / % 80.4
Elev. triglycerides (>1.7 mmol/L) / % 70.4
Elevated urea (>8 mmol/L) / % 67.4
Elev. creatinine (>140 μmol/L) / % 4.9
Smokers / % 18.8
Physically inactive / % 78.8
Duration of hypertension / year 16±4
Systolic blood pressure /mm Hg 176±15
Diastolic blood pressure /mm Hg 102±10
Mean arterial pressure /mm Hg 130±13
Pulse pressure /mm Hg 78±18
Frequency beats/min 76±4
BMI - body mass index
Table 1. Clinical characteristics of patients, with pressures
  LVH type (n pts.)
Medication Concentric Eccentric  Asymmetric  Total P 
 (n=91) (n=46) (n=50) (n=187)
ACE inhibitors or 67 (74%) 32 (70%) 42 (84%) 141 (75%) 0.52 
ARBs
Calcium 75 (82%) 36 (78%) 36 (72%) 147 (79%) 0.53 
antagonists
Beta blockers 46 (51%) 25 (54%) 29 (58%)  100 (53%) 0.74
Diuretics 41(45%) 23 (50%)  23 (46%)   87 (47%) 0.66
Anti-arrhythmics 17 (19%) 12 (26%) 8 (16%)   37 (20%) 0.37
ACE - angiotensin converting enzyme; ARBs - angiotensin receptor blockers; LVH - left 
ventricular hypertrophy
Table 2. Antihypertensive therapy (and anti-arrhythmics) applied in 
the examined population
  LVH type (LVMI g/m2)
LVH degree Concentric Eccentric  Asymmetric  Total P 
 (n=91) (n=46) (n=50) (n=187)
Mild (n=65) 145.18±12.53 164.49±22.35 145.29±18.21 150.41±17.92
Moderate 172.35±26.27 206.18±25.43 163.33±26.06 179.57±30.12 
(n=104)     0.001
Severe 204.18±44.63 214.75±0.11 204.97±30.92 207.22±36.43 
(n=18)
Total 165.82±23.46 181.42±37.41 170.27±14.59 173.25±27.18
LVH - left ventricular hypertrophy; LVMI - left ventricular mass index 
P=0.011 for eccentric versus concentric type
Table 3. Left ventricular mass index in patients with regard to the type 
and degree of left ventricular hypertrophy
Parameter Mean. v.±SD Range
QTi / ms 380.6±47.3 296-460
QTc / ms 425.0±34.4 255-496
QTd / ms 34.5±19.1 0-130
Table 4. Electrocardiographyc data (QT interval, QTc interval and QT 
dispersion)
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gender showed that the QTc interval in men with severe con-
centric and eccentric LVH was increased, but not significantly 
(p=0.081) (Fig. 1). Additionally, in the male group a simple regres-
sion analysis showed positive correlation between QTc interval 
and degree of LVH (Spearman rank r=0.26, p=0.031).
For the whole group of patients, QTd did not differ with 
regard to type and degree of LVH, although the analysis by gender 
again suggested that QTd values were significantly increased 
(p=0.047) in men with severe concentric and eccentric LVH (Fig. 2).
QTi was significantly longer (p=0.037) in patients with complex 
VA (Lown III-V) than in those with simple VA (Lown I-II) (Fig. 3). The 
QTc interval was also longer in patients with complex VA, but the 
difference was not statistically significant. 
Discussion
In our study, the average QTc interval for the entire group of 
patients was in the normal limits. Considering the entire patient 
group there was no significant association of QTi or QTc interval 
with the degree and type of LVH. However, in men with severe 
concentric and eccentric LVH the QTc interval values were 
higher, although statistically not significantly. As a result, the 
importance of asymmetric pattern was not confirmed. Regarding 
the degree of LVH, a positive correlation with QTc length, near to 
statistical significance, was observed only in men (p=0.081). The 
difference between genders can be explained by echocardio-
graphic measurements that confirmed anthropological differ-
ences (not shown in tables). Men had larger cardiac cavities 
(left ventricular internal diastolic diameter/left ventricular inter-
nal systolic diameter: 54.3/38.2 mm vs. 49.7/33.8 mm in women; 
p<0.001) and left ventricular mass (357.09 g/m2 vs. 303.34 g/m2, 
p<0.001). 
LVMI differed significantly (it increased) with regard to left 
ventricular hypertrophy degree (a measure of left ventricular 
geometry), suggesting appropriate stratification of patients. The 
significantly highest LVMI was found in patients with the eccen-
tric LVH type. The applied classification of left ventricular geo-
metric patterns was not performed in compliance with guide-
lines (13) because there was no reference to the asymmetric 
type of LVH. Moreover, IVS/LVPW ratio was not used in calcula-
tions. The classification used (considered in the literature 
before the guidelines were published) is to our judgment more 
accurate in differentiating the three LVH types.
Failure to attain statistical significance for QTc is possibly 
due to the small number of patients with severe degree of LVH. 
Such patients are difficult to find in larger number because in 
urban areas they are recognized and treated rather early before 
severe LVH has managed to develop. Moreover, it should also be 
taken into account that these patients, except for hypertensive 
cardiomyopathy, should have no other diseases (12). 
Consequently, not many articles investigating this correlation 
Figure 1. QTc interval in patients according to the type and degree of 
left ventricular hypertrophy. Presented are mean values with 95% 
confidence intervals
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Figure 2. QT dispersion in patients according to the type and degree of 
left ventricular hypertrophy. Presented are mean values with 95% 
confidence intervals
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Figure 3. QT interval in patients with simple (n=112) and complex 
VA (N=75). Presented are mean values with 95% confidence 
intervals
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have been published in the literature (1, 8). In some (22) QTc 
interval in patients with ventricular septal hypertrophy was sig-
nificantly longer than in the normal group. Researchers in (1) 
also obtained the correlation between QTi and LVMI lengths. 
There was no significant difference between QTd values with 
regard to the LVH degree and type in our study. However, QTd in 
men had again higher values in severe concentric and eccentric 
LVH. Such flawed results were certainly influenced by accurate 
measurements performed manually, which were not beyond 
reproach. Manual assessment of the T-wave end is extremely 
unreliable. Regrettably, the existing automated methods have not 
proven to be advantageous. The main source of mistakes for 
readers and computers are the low amplitudes of T waves and 
the border between the T and U wave or the P wave (9) so some 
new methods are under investigation (23, 24). Increased QTc 
dispersion was associated with LVH, especially with its concen-
tric variant in some studies (25, 26). In the LIFE study both con-
centric and eccentric LVH were associated with prolonged QTi 
and increased QTd (1). In another study (27) QTd >60 ms and QTi 
>440 ms were associated with greater probability of LVH. 
In our patients, the QTi length correlates with the VA inci-
dence. QTc interval was also longer in patients having complex 
arrhythmias but the difference in relation to simple arrhythmias 
was not significant. 
Several factors may influence the increased left ventricular 
ectopic activity in patients with LVH. Increased stimulation of 
hypertrophic myocytes, fibrosis in hypertrophic myocardium 
that leads to electrophysiological inhomogeneity, distention of 
certain myocytes, increased oxygen requirement of the myocar-
dium, damaged membrane porosity for various ions, and 
increased sympathetic activity are possible pathophysiological 
factors for the increased incidence of ventricular arrhythmias 
(28, 29).
In subjects without heart disease, during a 15-20 years fol-
low-up period, prospective studies found significant correlation 
between prolonged QTc interval and increased risk for coronary 
events (30), cardiovascular mortality and all-cause mortality 
(mean follow-up of 4.9 years) (31), as well as for sudden cardiac 
death or cardiovascular death (32). Patients with a prolonged 
QTc (>or=450 milliseconds in women and >or=440 milliseconds 
in men) had a nearly 2-fold increase in risks of coronary events 
and cardiovascular death (33). Increased QTd in patients with 
LVH and higher incidence of ventricular premature beats or 
complex ventricular arrhythmias was also described by other 
authors (10). Both men and women with hypertension and left 
ventricular hypertrophy had significantly lower HR and higher 
values of QT interval dispersion compared with hypertensives 
with normal left ventricular geometry (30). Özdemir et al. (34) 
studying 80 patients with concentric LVH have found strong cor-
relation between increased QTd and the incidence of ventricu-
lar arrhythmias. Other authors (35) obtained the highest influ-
ence of asymetric LVH on QTd, but without correlation between 
ventricular premature beats and QTd, neither between ventricu-
lar premature beats and LVMI.
Medications were discontinued 48 hours prior to ergometric 
examination and Holter monitoring with the intention to avoid the 
effects of treatment duration and type of antihypertensive and 
anti-arrhythmic drugs [applied in patients with complex ventricu-
lar arrhythmias (Lown III-V)] on the outcome. We observed 
whether these parameters differed between the examined groups. 
The obtained result was negative. A longer suspension of treat-
ment could have threatened the patient or lead to reduced coop-
eration. Withdrawal of beta-blockers could have affected the 
increase of cardiac rate and rhythm control; however, all three 
study groups were under identical conditions. None of the anti-
arrhythmic medicines has half-life longer than 48 hours (digoxin 
36-48 hours, verapamil 2.8-7.4, atenolol 6-7, carvedilol 7-10, biso-
prolol 10-12, mexiletine 9-11 and propafenon 2-10 hours).
According to some investigations patients with increased QTd 
should be treated with angiotensin receptor blockers and nebivo-
lol (36, 37). Telmisartan-based treatment induced an increased 
vagal activity without significant change of sympathetic activity 
and a reduction of QT dispersion and QTc dispersion (36).
Study limitations
It was impossible to rule out coronary heart disease com-
pletely. Coronary angiography is not indicated in all asymptom-
atic patients and myocardial stress-scintigraphy is too expen-
sive and time-consuming. Modified methods from other similar 
studies were therefore applied. A 48-hour antihypertensive drug 
withdrawal period is relatively short. We studied the duration of 
treatment and the type of antihypertensive and anti-arrhythmic 
drugs and found no differences between the examined groups. 
Our small subgroup of patients with severe degree of LVH 
was analyzed with appropriate statistical methods. An inadver-
tent inclusion of a patient with hypertrophic cardiomyopathy 
(HCM) and hypertension had probably no effect on the results 
considering the very small prevalence of this disease.
Conclusion
There was no significant association of QTi or QTc interval with 
the degree and type of LVH. Analyses by gender showed that men 
with severe concentric and eccentric LVH had higher values of 
QTc interval and QTd than those with asymmetric LVH (not signifi-
cant). Considering only the degree of LVH, a positive and significant 
correlation for the QTc interval length was found again only in men. 
QTi was significantly longer in patients with complex ventricular 
arrhythmias (Lown III-V) than in those with simple VA (Lown I-II). 
QTc interval had the same tendency. Eccentric LVH showed maxi-
mal values of all studied parameters only in men. These findings 
could suggest the greater arrhythmogenecity of the concentric and 
eccentric in relation to the asymmetric LVH type.
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